Surgery for the failing heart after myocardial infarction

Miyokard infarktüsü sonrası gelişen kalp yetersizliğinde cerrahi

Constantine L. Athanasuleas, Gerald D. Buckberg

Department of Cardiothoracic Surgery, School of Medicine, University of Alabama, Birmingham, Alabama

1Division of Cardiothoracic Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA

ABSTRACT

Function follows form and this maxim provides an understanding of the pathophysiology of congestive heart failure following myocardial infarction. The heart fails as it enlarges and becomes more spherical. Surgical methods to treat dilated ischemic cardiomyopathy have evolved and been applied to thousands of patients worldwide. Known as "surgical ventricular restoration", or SVR, the operation reduces left ventricular volume and restores the ventricle towards a more conical normal shape. Global systolic function is improved. Mechanical synchrony is restored. Arrhythmias are largely abated. Neurohumoral mediators that stimulate continued ventricular enlargement are largely reduced. Finally, there is marked and sustained symptomatic improvement of congestive heart failure post-infarction patients after SVR.

(Anadolu Kardiyol Derg 2008; 8: Suppl 2; 93-100)

Key words: Surgical ventricular restoration, myocardial infarction, chronic heart failure, outcomes

ÖZET


Anahtar kelimeler: Ventrikülün cerrahi oranı, miyokard infarktüsü, kronik kalp yetersizliği, sonuçlanın noktaları

Introduction

Congestive heart failure (CHF) is an epidemic in the industrial world and consumes a major portion of the health care costs of many nations. Coronary artery disease continues to be the major cause of heart failure followed by valvular heart disease. The majority of heart failure cases is caused by coronary artery disease, and a major proportion of these is associated with prior myocardial infarction (1). Drug therapy has improved and heart failure clinics are very influential in reducing acute hospital visits, but the outcome of class III and IV heart failure secondary to ischemic disease continues to be poor. Destination therapy with ventricular assist devices is costly and the long-term results, though improving, are still rather dismal. Cardiac transplantation, another alternative, is both costly and limited by the donor sources.

Increasingly, the standard of care in the treatment of patients with acute myocardial infarction is prompt restoration of blood flow to the infarct-related coronary artery. This is achieved by pharmacologic means or more commonly by acute percutaneous stenting interventions. Despite these efforts, many patients develop progressive dilation of the ventricle leading to congestive heart failure. In this section, we shall elucidate the interaction of form with function and offer surgical approaches in the treatment of heart failure in patients with dilated left ventricles following anterior myocardial infarction, the so-called “surgical ventricular restoration” (SVR) operation.
Shape, size, and function

The normal heart is a conical structure as first described by Hippocrates and Galen. A helical spiral at the cardiac apex was noted several hundred years ago and thought to be responsible for the force of ventricular ejection. Exactly how the spiral architecture of the myocardium relates to function has been revealed by Francisco Torrent-Guasp who systematically dissected mammalian hearts and linked form with function (2). His work, dating back to the 1950's, has become the basis of how the heart functions in both health and disease. He spatially unfolded the intact heart by macroscopic dissection, demonstrating a muscular band that begins at the pulmonary artery and ends at the aorta. This band contains a myocardial fold that separates the heart into two simple loops called the “basal” and “apical” loops. The structural components include a horizontal or transverse fiber orientation for the basal loop that surrounds the right and left ventricles, and a change in fiber direction through a spiral fold in the ventricular band to form a ventricular helix that now contains obliquely oriented fibers. These form descending and ascending segments of the apical loop with an apical vortex. These components are shown in Figure 1. The helical architecture of the normal heart has been confirmed by strain relationships using magnetic resonance imaging (MRI), corrosion casts showing spiral architecture, and by sonomicrometry. Each pattern reflects the normal oblique fiber orientation that conveys maximum force during ejection and suction (3).

The mechanism of normal myocardial contractility described the Torrent-Guasp model also explains myocardial dysfunction in diseased states. His model asserts that myocardial shape is the major determinant of global systolic ejection. The normally oriented oblique myocardial fibers produce an ejection fraction of approximately 60%. The infarcted dilated ventricle becomes spherical and the myocardial fibers become transversely oriented (Fig. 2). When this occurs, the ejection fraction falls sharply to about 30%, even when the intrinsic fiber shortening of the myocytes remains normal (4). This architectural disadvantage limits deformation (twisting) that is visible at operation or by MRI and speckle echocardiography, negatively impacting the natural increment of strain development from mid-wall to apex (5). This further impairs sequential contraction efficiency and reduces ventricular function by producing mechanical dysynchrony (6). Left ventricular and global ventricular dilation are the morphological consequences seen in congestive heart failure patients due to ischemic or non-ischemic causes. In ischemic disease, there is necrosis of myocardium that leads to remodeling. In non-ischemic disease, there is also a component of scar formation that is not necessarily uniform. The treatment of acute myocardial infarction by early reperfusion by thrombolysis or angioplasty has largely been successful in ameliorating left ventricular enlargement, but is not totally successful. Important data regarding this finding came years ago from the GUSTO study in which ventricular volumes were measured by right anterior oblique (RAO) ventriculography shortly after successful thrombolysis of an occluded coronary artery (7). Despite successful reperfusion of the infarct-related artery, 17% of patients had a left ventricular end-systolic volume index (LVESVI) greater than 40 ml/m2 (normal LVESVI is 25 ml/m2). Progressive congestive heart failure and death rates were correlated with increasing ventricular volumes above this value. These findings were confirmed in another study that documented early LVESVI greater than 50 ml/m2 in 20% of patients after successful recanalization of the infarct-related artery. In such patients, ventricular dilation over three years led to congestive heart failure by progressive dysfunction of the remote non-infarcted myocardium (8). Interestingly, LVEVSI, not ejection fraction, most closely predicts outcome in dilated cardiomyopathy, a fact poorly appreciated by most cardiologists in clinical practice (Fig. 3, 4) (9). Moreover, for a given ejection fraction, there may be a wide range of ventricular volume in ischemic cardiomyopathy (Fig. 5).

Increased ventricular size after infarction has other deleterious effects on myocardial function that intensifies congestive heart failure. Mitral leaflet coaptation is reduced as the papillary muscles widen, causing tethering of the mitral apparatus. The
ensuing mitral regurgitation raises ventricular volume reducing forward cardiac output. Increased ventricular size also promotes ventricular dysrhythmias and can cause dyssynchronous mechanical contraction. This may be a contributing factor in sudden death (10, 11).

Principles of surgical therapy

The goals of surgery are reduction in volume and restoration of shape toward normalcy. These are based on the principle outlined above, namely that form defines function. Surgical ventricular restoration refers to operations that treat patients with ventricular dilation and congestive heart failure after myocardial infarction. These include the classic left ventricular aneurysmectomy, either by plication or by endoaneurysmorrhaphy, described years ago and applied to thinned transmural scars resulting from coronary occlusions. In this era, such pathology is rarely seen, since infarction is treated early and aggressively by coronary revascularization, either by thrombolysis or percutaneous intervention. Hence, the morphologic appearance of the post-infarct segment is not one of dyskinesia, but rather akinesia. Vincent Dor first described intraventricular infarct exclusion for the akinetic ventricle, recognizing that the adverse physiologic and hemodynamic consequences of ventricular dilation in the presence of akinesia or dyskinesia were the same (12, 13). During SVR, the infarcted segment of the left ventricle is excluded, usually with an intraventricular patch, thereby creating a smaller and more elliptical ventricular chamber (Fig. 6).

Surgical ventricular restoration should not be confused with partial left ventriculectomy, the so-called “Batista procedure”, in which the lateral wall was resected to reduce ventricular volume in patients with dilated cardiomyopathy whose etiology was either ischemic or non-ischemic. This was a non-selective resection, and in cases of non-ischemic cardiomyopathy, often removed the segment of ventricle that was functional. Partial left ventriculectomy has largely been abandoned in the treatment of ischemic cardiomyopathy due to poor long-term outcomes (14). Surgical ventricular restoration should not be isolated procedure. In fact, it usually is performed concomitantly with coronary bypass grafting and mitral valve repair when there is a significant functional mitral regurgitation. Attempts to treat ischemic mitral valve regurgitation at the annular level (ring annuloplasty) is not as predictable or durable as once thought, because the mechanism of such mitral regurgitation is related to the interaction of the mitral apparatus and the ventricle (15). Surgical ventricular restoration treats the three “Vs” of congestive heart failure: vessels, valve, and ventricle.

Preoperative evaluation

Candidates for the SVR operation typically have a history of remote infarction months to years prior to operation and symptoms of advanced congestive heart failure (NYHA class III or IV). Electrocardiography confirms prior infarction in all cases.
Such patients may or may not have angina, but since coronary artery disease is the major causative factor, coronary angiography is essential. Evaluation of left ventricular size and function is crucial in assessing operability and determining adjunctive procedures. This is done with echocardiography, ventriculography or cardiac magnetic resonance imaging (CMR). Each method has advantages and limitations.

Echocardiography is readily available. It can be used to confirm ventricular enlargement by measurement of the short axis, calculate systolic ejection fraction, and determine diastolic function. Clinicians often report left ventricular end-diastolic dimension (LVEDD). This dimension is often misleading because it measures the distance between the bases of the papillary muscles. Anterior infarction often results in non-homogeneous structural changes and myocardial damage may occur distal to the traditional point of measurement. Consequently, LVEDD can be normal, even in the presence of a large akinetic or dyskinetic anteroseptal wall as a result of anterior myocardial infarction. Left ventricular end-diastolic dimension is more useful during the later stages of ventricular remodeling in ischemic cardiomyopathy after global dilation occurs and in non-ischemic cardiomyopathy with global dilation. The extent of regional asynergy of the infarcted segment can be visualized, as can the wall motion and thickness of the remote non-infarcted segments. An asynergic (non-contracting region with either akinesia or dyskinesia) area greater than 35% warrants intervention. After anterior myocardial infarction, the finding of normal motion and thickening of the lateral and inferior walls (remote muscle) is important in determining operability. Exact left ventricular volume determination by echocardiography is not very reliable and alternative methods are discussed below.

Ventriculography in the RAO view confirms asynergy of the anterior and apical segments after anterior infarction, but does not reveal septal or lateral wall function. These segments are best viewed in the left anterior oblique (LAO) view. Data from both views are used to determine left ventricular volume. If only a RAO view is available, volume will generally be underestimated, but will at least confirm significant enlargement. Left ventricular end-systolic volume index greater than 60 ml/m² is a generally agreed threshold for surgical intervention.

If there is akinesia or severe hypokinesia of the remote non-infarcted segments due to ischemia or prior infarction, then myocardial viability tests are needed to determine the degree of reversible function. Dobutamine echocardiography is used for evaluation of viability. While thallium scintigraphy may be useful, it is limited because this test does not determine transmurality of the infarcted region. A major thickness of ventricle may be scar, but the veneer of normal epicardium may take up thallium and lead to false conclusions. Cardiac magnetic resonance imaging with delayed gadolinium enhancement is the most predictive test of viability and reversibility of function in hypokinetic segments following infarction (Fig. 7). Cardiac MRI allows determination of regional wall thickening and accurate calculation of global systolic ejection fraction. It is also the most accurate method of measuring ventricular volumes.

The preoperative workup is not complete without assessment of mitral valve function. Late failure of SVR is related to untreated mitral regurgitation at the initial operation (16). Global left ventricular enlargement can cause mitral regurgitation that occurs at rest or with exertion. The associated anatomic changes include annular dilatation, decreased leaflet coaptation, and widening of the papillary muscle insertion sites due to scar. The mitral valve function should be determined preoperatively by history, physical examination and echocardiography. We recommend mitral repair if there is 2 to 4+ mitral regurgitation, or if the mitral annulus exceeds 35 mm in diameter even in the absence of mitral regurgitation. In such cases, there is usually limited leaflet coaptation that may be functionally significant causing congestive symptoms with exercise. The vast majority of mitral interventions during SVR are mitral valve repair with annuloplasty. However, excessive scarring involving the inferior or lateral walls may warrant mitral valve replacement with preservation of the subvalvular apparatus.

**SVR: the operation**

Ventricular restoration requires sternotomy and cardiopulmonary bypass. In the majority of cases, coronary bypass and mitral valve repair with annuloplasty is done by conventional means with cardioplegic protection of the myocardium. The ventricular portion of the operation then follows. Some surgeons do this part of the operation with the heart arrested, and others prefer to allow the heart to beat. The empty, vented open heart allows for precise visual and palpable identification of the contracting and non-contracting segments. In either case, an encircling suture is placed in the myocardium at this juncture and tightened. This forms a ledge, or platform for the placement of an endovascular patch (Dacron or bovine). The residual myocardium is closed over this patch to aid in hemostasis. Alternately, some surgeons prefer to isolate the scarred segment by a series of circular sutures to reduce the ventricular volume. Postoperative management is routine and includes early use of beta-blockers and angiotensin-converting enzyme inhibitors. Oral anticoagulation is indicated if mitral valve repair is done, as usual, for three months. Aspirin is also prescribed if concomitant coronary bypass is performed.
Outcome of SVR surgery

Dor’s experience in treating congestive heart failure by ventricular volume reduction inspired a multinational study of ventricular restoration (17). A collaborative group of cardiologists and cardiac surgeons (the RESTORE Group) from four continents (USA, Europe, Asia, South America) applied SVR in 1198 patients between 1998 and 2003 (30). Patients were included in the registry if SVR was performed for the following: prior anterior myocardial infarction with significant ventricular dilation (LVESVI ≥60 ml/m²), and a regional asynergic (non-contractile) area of ≥35%. Surgical ventricular restoration was most often done as a concomitant procedure: 90% received coronary bypass grafting and mitral valve repair was required in about 20%.

In the RESTORE registry, 86% of patients had NYHA class III/IV symptoms of CHF preoperatively. Such patients have a high mortality with medical therapy, or with surgical revascularization without left ventricular restoration, where late deaths are attributable mainly to CHF. Echocardiography, ventriculography or cardiac magnetic resonance angiography were used to confirm the asynergic area and calculate the ejection fraction. Left ventricular end-systolic volume was determined by ventriculography or CMR in all cases.

Hospital mortality after SVR was 5.3%, and increased as preoperative ventricular volume rose: 2.3% if LVESVI was < 60 ml/m², 5.7% if LVESVI was 60-90 ml/m², 8.1% if LVESVI was 90-120 ml/m² and 8.4% if LVESVI was >120 ml/m². These findings are comparable to recently reported mortality rates (5.5%-11%) in ischemic patients with left ventricular dysfunction (EF <35%) undergoing coronary artery bypass grafting alone. The addition of mitral valve repair influenced early outcome. Hospital mortality was 8.7% with mitral repair vs. 4.0% without repair (p<0.001). Perioperative mechanical support with intra-aortic balloon pumping was uncommon (<9%). Global systolic function improved postoperatively as ejection fraction (EF) increased from 29.6±11.0% preoperatively to 39.5±12.3% postoperatively (p<0.001). Left ventricular end-systolic volume decreased from 80.4±51.4 ml/m² preoperatively to 56.6±34.3 ml/m² postoperatively (p<0.001).

The overall five-year probability of survival after SVR was 68.6±2.8% and confirms Dor’s extensive experience. A detailed analysis of these findings has been reported for each volume subset (17). Multivariate analysis of SVR demonstrated that major risk factors were age, preoperative EF, LVESVI, and NYHA functional class.

The RESTORE data further emphasized the importance of measuring LVESVI as a surrogate marker of left ventricular function. Ejection fraction and LVESVI are not directly related, as there is a wide variation in volume for a given EF (33). Patients with preoperative LVESVI ≤80 ml/m² had long-term survival of 79.4±3.3% as compared to 67.2±3.2% for those with larger hearts. Preoperative NYHA functional class was also predictive of outcome with decreased five-year survival in patients with preoperative NYHA class IV symptoms (49.7±5.8% vs. 69.9±4.7% in class III). These predictors of long-term outcome after SVR are similar to those previously reported (18). A small number of patients (9%) with functional class I symptoms underwent SVR as an adjunct to coronary artery bypass surgery (CABG) because of ventricular dilation (LVESVI >80 ml/m²), which has been shown to be a precursor of late development of CHF and early death (7).

The experience of many other centers has confirmed the findings of the RESTORE group. The cumulative experience now includes seven thousand cases, and is increasing daily (12, 17-27) (Fig. 8). Despite this wide experience, only one study has matched patients with depressed systolic function treated by CABG alone vs. CABG and SVR (28). In this study, operative results were similar, but functional class, readmissions to the hospital for heart failure, and short-term survival were better in the SVR plus CABG group. The ultimate prospective trial to evaluate CABG vs. SVR plus CABG is an ongoing study called the STITCH trial, sponsored by the National Institute of Health in the USA. Whatever the upcoming results may be, these must be compared to the RESTORE data, which serve as a benchmark for surgical efficacy (29).

Physiologic and clinical effects of SVR

There are many measures of ventricular function in ischemic cardiomyopathy. One, which has received much attention, is asynchrony seen so often in diseased dilated hearts. Cardiac resynchronization therapy (CRT) has emerged as a major industry. Expensive implantable devices abound, but are ineffective in about a fourth of patients and investigators are still searching for criteria that identify failure of this treatment. An intriguing finding after SVR is the effect on ventricular synchrony. A recent analysis of 30 consecutive patients undergoing SVR showed that preoperative LV contraction was highly asynchronous, because pressure/volume (P/V) loops displayed abnormal isometric phases with a right shifting (6). Moreover, endocardial time motion was either early or delayed at the end-systolic phase as demonstrated by the pressure/length (P/L) loops, which were markedly abnormal in size, shape, and
Norepinephrine, angiotensin II, and plasma renin activity fall after neurohumoral axis that aggravates and furthers heart failure. Cseh & Pohost (26) had postoperative induced arrhythmia by paired ventricular stimulation and were successfully treated with amiodarone. Very few patients fractions were below 35% might have otherwise undergone defibrillator placement as the MADIT criteria suggest. Many of these patients whose ejection fractions were below 35% might have otherwise undergone defibrillator placement as the MADIT criteria suggest.

If SVR had not been performed, many of these patients whose ejection fractions were below 35% might have otherwise undergone defibrillator placement as the MADIT criteria suggest. Very few patients whose ejection fractions were below 35% might have otherwise undergone defibrillator placement as the MADIT criteria suggest. Many of these patients whose ejection fractions were below 35% might have otherwise undergone defibrillator placement as the MADIT criteria suggest.

Another intense focus of interest in the treatment of cardiomyopathy is that of arrhythmias. Implantable defibrillators have been routine in clinical practice and are used in patients with prior infarctions and EF below 35% (the MADIT criteria) (30). This treatment was stimulated by the SAVE (Survival and Ventricular Enlargement Trial) trial, which showed a correlation between ventricular arrhythmia and increased ventricular size and shape (31). Interestingly, SVR, by reducing ventricular size, also treats ventricular arrhythmias. In a subset of patients studied in the RESTORE group, investigators examined 382 patients with electrophysiological testing (32). They found a clear relationship between ventricular arrhythmia and increased ventricular size and shape (31).

A remarkable return of synchrony following SVR (Fig. 10, 11) (6). Surgical ventricular restoration shifted the P/V loops leftwards towards normal and the P/L loops almost normalized demonstrating cardiac resynchronization (Fig. 9). Analysis of individual myocardial segments by the centerline method showed a remarkable return of synchrony following SVR (Fig. 10, 11) (6). Hemodynamic measurements after SVR indicated improved systolic function (EF increased from 30±13% to 45±12%; p=0.001). Diastolic function also improved evidenced by a more rapid peak-filling rate.

Another salutary effect of SVR is its effect on the treatment of cardiomyopathy that is that of arrhythmias. Implantable defibrillators have been routine in clinical practice and are used in patients with prior infarctions and EF below 35% (the MADIT criteria) (30). This treatment was stimulated by the SAVE (Survival and Ventricular Enlargement Trial) trial, which showed a correlation between ventricular arrhythmia and increased ventricular size and shape (31). Interestingly, SVR, by reducing ventricular size, also treats ventricular arrhythmias. In a subset of patients studied in the RESTORE group, investigators examined 382 patients with electrophysiological testing (32). They found a clear relationship between ventricular arrhythmia and increased ventricular size and shape (31). Interestingly, SVR, by reducing ventricular size, also treats ventricular arrhythmias. In a subset of patients studied in the RESTORE group, investigators examined 382 patients with electrophysiological testing (32). They found a clear relationship between ventricular arrhythmia and increased ventricular size and shape (31).

As we have seen, SVR reduces LV volume, changes LV shape, and improves global systolic function. Why this happens is postulated as follows: myocardial oxygen consumption (MVO2) is closely related to wall tension, which in turn, is related to the radius of the ventricle. If the ventricle is spherical, then the ventricular volume (V) is related to radius (r) as follows: V = 4/3π·r3. Substituting this relationship into the LaPlace...
relationship, tension (T) is related to $P \cdot \sqrt[3]{V}$. However, if the ventricle is cylindrical, then tension is reduced by its relation to the square of the radius: $P \cdot \sqrt{V}$. Deformation increases and efficiency improves as the ventricle anisotropically thickens and the chamber dimension narrows towards the apex. Recovery of remote muscle function has been demonstrated after SVR by magnetic resonance tagging; circumferential shortening and deformation improved (34).

**Conclusion**

Ventricular scar post-infarction is the "culprit lesion" that initiates and perpetuates a cascade of neurohumoral mediators in the heart leading to progressive left ventricular dysfunction and clinical symptoms of congestive heart failure. The morphological consequence of increased ventricular sphericity and volume are
treated by surgical ventricular restoration, an operation that reduces LV volume while reshaping the ventricle toward a more conical structure. Global systolic and diastolic ventricular function is improved, remote non-infarcted muscle function is enhanced, synchrony is restored, adverse neurohumoral mediators are turned off, and arrhythmogenesis is largely abated. The worldwide experience with SVR is now extensive and shows excellent functional and long-term outcomes. Cardiologists are encouraged to view these positive results in their evaluation of patients with dilated left ventricles and heart failure following myocardial infarction.

References